公司资料

Viatris Inc. 股价、新闻与催化剂

股票代码:
VTRS
交易所:
NASDAQ
行业:
Generics, Small Molecule Drugs
所在地:
United States

股票表现

17.46 USD (-1.47%)

收盘价

最后更新: 2026年10月1日

18.3B USD

市值

股价为何变动

截至 2026年10月1日,VTRS 下跌 1.47%,收于 $17.46。当前新闻监测窗口内未发现新的同公司新闻。

公司概览

Global Medicines Company

Viatris is a global healthcare company that develops, manufactures, and commercializes branded medicines, generic drugs, complex products, and biosimilars. Its portfolio is distributed across developed and emerging markets through a broad manufacturing, regulatory, and commercial network.

Established Brands Portfolio

The company's established brands include medicines used in cardiovascular disease, central nervous system disorders, respiratory disease, infectious disease, and other chronic conditions. These products often rely on geographic expansion, lifecycle management, and durable physician familiarity rather than exclusively on new molecular innovation.

Generics and Complex Products

Viatris manufactures oral solids, injectables, transdermal products, respiratory medicines, and other technically complex dosage forms. Scale in development, manufacturing, and regulatory submissions allows the company to supply a wide range of affordable medicines across multiple regions.

Biosimilars Business

The biosimilars portfolio gives Viatris exposure to large biologic markets through products referencing established therapies in oncology, immunology, diabetes, and other specialties. Commercialization is frequently conducted through regional partnerships that divide development, manufacturing, and market responsibilities.

Pipeline and Portfolio Management

Viatris combines internal development with licensing, partnerships, acquisitions, and divestitures to reshape its portfolio. New products include Gwyn Lo, while MR-107A-02 is being developed as a fast-acting, non-opioid meloxicam formulation for moderate-to-severe acute pain.

未来催化剂

  • Commercial availability of Gwyn Lo later in 2026.
  • FDA PDUFA decision for MR-107A-02 in moderate-to-severe acute pain on December 27, 2026.

近期新闻

新闻标题由机器翻译,详情为英文原文。

    相似股票

    商业成熟度、治疗领域或催化剂模式相近的同行公司。